May 24, 2022

FTC v. Endo Pharmaceuticals Inc., et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. August 25, 2023

    DC Circ. Won't Revive FTC's Endo-Impax Deal Suit

    A D.C. Circuit panel refused Friday to revive a Federal Trade Commission lawsuit targeting an opioid medication settlement between Endo Pharmaceuticals and Impax, concluding the license brandmaker Endo granted for Impax to sell a generic, even the only version of the drug available, was just "a standard exclusive license."

6 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login